Lenvatinib information

Lenvatinib
Clinical data
Trade names	Lenvima, others
Other names	E7080
AHFS/Drugs.com	Monograph
License data	US DailyMed: Lenvatinib;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth
ATC code	L01EX08 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	85% (estimated)
Protein binding	98–99%
Metabolism	CYP3A4, aldehyde oxidase, non-enzymatic
Metabolites	Desmethyl-lenvatinib (M2) and others
Elimination half-life	28 hours
Excretion	~65% feces, 25% urine
Identifiers
	IUPAC name 4-[3-Chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide;
CAS Number	417716-92-8 ;
PubChem CID	9823820;
IUPHAR/BPS	7426;
DrugBank	DB09078 ;
ChemSpider	7999567 ;
UNII	EE083865G2;
KEGG	D09919 ; as salt: D09920 ;
ChEBI	CHEBI:85994 ;
ChEMBL	ChEMBL1289601 ;
CompTox Dashboard (EPA)	DTXSID50194605 ;
Chemical and physical data
Formula	C21H19ClN4O4
Molar mass	426.86 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C4CC4NC(=O)Nc3ccc(cc3Cl)Oc1ccnc(cc2OC)c1cc2C(=O)N;
	InChI InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28) ; Key:WOSKHXYHFSIKNG-UHFFFAOYSA-N ;
	(what is this?) (verify)

Lenvatinib, sold under the brand name Lenvima among others, is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.^[4]

^ "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
^ "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
^ "Kisplyx EPAR". European Medicines Agency. 25 August 2016. Retrieved 7 January 2024.
^ Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M (September 2008). "Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase". Clinical Cancer Research. 14 (17): 5459–65. doi:10.1158/1078-0432.CCR-07-5270. PMID 18765537.

[1] "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.

[2] "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.

[Kisplyx_EPAR-3] "Kisplyx EPAR". European Medicines Agency. 25 August 2016. Retrieved 7 January 2024.

[4] Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M (September 2008). "Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase". Clinical Cancer Research. 14 (17): 5459–65. doi:10.1158/1078-0432.CCR-07-5270. PMID 18765537.

Lenvatinib information

and 29 Related for: Lenvatinib information

Lenvatinib

Beacon Pharmaceuticals

Insulin

Trastuzumab deruxtecan

Erythropoietin

Fruquintinib

Lorlatinib

Cerebrolysin

Filgrastim

Cetuximab

Bevacizumab

Amitriptyline

Wnt signaling pathway

Dehydroepiandrosterone

List of drugs granted breakthrough therapy designation

Tyrosine kinase inhibitor

HER2

Trastuzumab

Growth factor

Toni Choueiri

Thyroid cancer

Trastuzumab emtansine

Trametinib

Erlotinib

Integrin

Thrombopoietin

Pegfilgrastim

Dasatinib

Dexamethasone